Organisation paid for research Program year 2024 Source: CMS Open Payments

Wallace Rheumatic Studies Center LLC

Neither a doctor nor a teaching hospital

Research payments

$422,071

33 payments

Through program year 2024, Wallace Rheumatic Studies Center LLC is reported as receiving $422,071 in research payments, across 33 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$20,008	3
2023	Research	$9,103	4
2022	Research	$72,464	6
2021	Research	$112,868	9
2020	Research	$107,671	5
2019	Research	$99,958	6

Breakdown

Who paid Research payments · program years 2019–2024

Eli Lilly and Company $336,865 9 payments
Aurinia Pharma U.S., Inc. $28,520 8 payments
Amgen Inc. $25,814 7 payments
Gilead Sciences, Inc. $12,750 4 payments
Genentech, Inc. $9,288 2 payments
Pfizer Inc. $8,835 3 payments

Studies the money was for Research payments · program years 2019–2024

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $271,338 5 payments
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (Sle) $65,527 4 payments
A Randomized, Controlled Double-Blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 MG Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis $16,756 2 payments
DAZ-301 P3 DAZ Efficacy/Safety in Mod-Severe SS $11,758 2 payments
Randomised Double Blind Study to Evaluate Safety and Efficacy of Obinutuzumab in Class III and IV LN $9,288 2 payments
LUPKYNIS Registry Study $9,103 4 payments
A Ph2 Doubleblind Randomized Placebocontrolled Multicenter Doseranging Study to Evaluate the Efficacy and Safety Profile of Pf06700841 in Subjects With Systemic Lupus Erythematosus $8,395 2 payments
A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects with Cutaneous Lupus Erythematosus (CLE) $8,250 1 payment
DAZ-303 P3 DAZ Efficacy/Safety in SS w/ESSPRI >5 $8,250 1 payment
Ph 1b in Subjects with SLE $4,958 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.